Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 1

Conditions

Myelodysplastic Syndromes 7Lymphoma, Follicular 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Prolymphocytic 4Leukemia 4Burkitt Lymphoma 4Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Primary Myelofibrosis 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

rasburicase 2Urate Oxidase 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tumor Lysis Syndrome × Allopurinol × Myeloid × Clear all
NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡